Bill Chin, MD
Executive VP, Translational Medicine
Bill is the Executive Vice President (EVP), Clinical and Translational Science at Frequency Therapeutics, having previously served as interim Chief Medical Officer. Before joining Frequency, he was the EVP for Science and Regulatory Advocacy and CMO at the Pharmaceutical Research and Manufacturers of America (PhRMA) where he led PhRMA’s continuing efforts in science and regulatory advocacy in the drug discovery and development ecosystem.
Prior to PhRMA, Bill was the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School. Before that, he was at Eli Lilly and Company, last as Senior Vice President for Discovery Research and Clinical Investigation.
Bill is a Harvard-trained endocrinologist and longstanding faculty member with an extensive bibliography of over 300 papers, chapters and books. During his 25 years on the Harvard Medical School faculty, Bill was Chief of the Genetics Division in the Department of Medicine at the Brigham and Women’s Hospital, a Howard Hughes Medical Institute investigator and Professor of Medicine.
As a pioneering molecular endocrinologist, Bill embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. He has been honored with numerous awards for research, mentorship and leadership. Bill received his A.B. in Chemistry from Columbia University and his M.D. from Harvard Medical School.